Eli Lilly's Fast-Acting Insulin Lispro Receives CHMP's Positive Opinion in Patients with Diabetes
Shots:
- The approval is based on two studies- PRONTO-T1D & PRONTO-T2D assessing fast-acting insulin lispro (URLi) vs Humalog both in combination with insulin glargine/ degludec in 1-222 & 673 patients with T1D & T2D respectively
- The PRONTO-T1D & PRONTO-T2D resulted in meeting 1EPs of non-inferior A1C reduction @26wks.- reduction in blood glucose spikes at both one and two hrs. following a test meal
- The fast-acting formulation of insulin lispro- currently being evaluated in adults with T1D & T2D. If approved- it will be commercialized under the trade name Liumjev in the EU
Click here to read full press release/ article
Ref: Eli Lilly | Image: Eli Lilly
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com